Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gilead Sciences Launches Five-Year WHO Partnership to Accelerate Elimination of Visceral Leishmaniasis in High-Burden Regions

Fineline Cube May 22, 2026
Company Deals

Johnson & Johnson Partners with Abu Dhabi DOH to Launch Global Surgical Intelligence Network Powered by Polyphonic Platform

Fineline Cube May 22, 2026
Company Deals

Eli Lilly Acquires Engage Biologics for $202M to Bolster Genetic Medicines Portfolio with Tethosome Platform

Fineline Cube May 22, 2026
Company Deals

Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network

Fineline Cube May 21, 2026
Company Deals

Medtronic to Acquire SPR Therapeutics for $650 Million, Expanding Chronic Pain Management Portfolio

Fineline Cube May 21, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Allergan Aesthetics Secures CHMP Positive Opinion for Boey (TrenibotulinumtoxinE) in Glabellar Lines Treatment Across European Economic Area

Fineline Cube May 23, 2026
Company Drug

Lupeng Pharma Enrolls First Patient in Global Phase 3 ROCKET-CLL Trial of Fourth-Gen BTK Inhibitor Rocbrutinib vs. Pirtobrutinib

Fineline Cube May 23, 2026
Company Deals Digital

Cowell Health Partners with Gilead Sciences to Enhance Drug Accessibility

Fineline Cube Jan 18, 2023

Cowell Health has announced a partnership with US-based Gilead Sciences, Inc., (NASDAQ: GILD) aimed at...

Company Deals

IASO Bio Raises RMB 500 Million in Series C1 Funding for Cell Therapy Pipeline

Fineline Cube Jan 18, 2023

China-based IASO Biotherapeutics has announced the completion of a nearly RMB 500 million (USD 73.7...

Company Drug

Junshi Biosciences’ COVID-19 Drug JT001 (VV116) Accepted for NMPA Review

Fineline Cube Jan 18, 2023

China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that its oral nucleoside analog drug...

Company Drug

Bristol-Myers Squibb’s Opdivo Gains New Indication for NSCLC Neoadjuvant Therapy in China

Fineline Cube Jan 17, 2023

US-based pharmaceutical giant Bristol-Myers Squibb (BMS, NYSE: BMY) has secured another indication approval in China...

Company Drug

Daiichi Sankyo’s Mirogabalin Nears China Market Entry with CDE Review

Fineline Cube Jan 17, 2023

Japan-based Daiichi Sankyo Inc. (TYO: 4568) has announced that China’s Center for Drug Evaluation (CDE)...

Company Drug

Bio-Thera’s Biosimilar BAT1806 Passes NMPA Review, Targets Roche’s Actemra

Fineline Cube Jan 17, 2023

China-based Bio-Thera Solutions Ltd (SHA: 688177) has announced that its biosimilar drug BAT1806, modeled after...

Company Drug

Abbisko’s ABSK021 Gains NMPA Approval for Phase II Study in cGVHD

Fineline Cube Jan 17, 2023

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced receiving approval from the National...

Company Deals

AffaMed Secures China Rights to Eli Lilly’s Migraine Drug Galcanezumab

Fineline Cube Jan 17, 2023

China-based AffaMed Therapeutics has announced an agreement with Eli Lilly and Company to obtain sole...

Policy / Regulatory

China’s NHC Releases Second National Drug Use Monitoring List

Fineline Cube Jan 17, 2023

China’s National Health Commission (NHC) has released the second national drug use monitoring list, covering...

Company Deals

Suzhou Powersite Electric Secures Series B Funding for X-ray Imaging Expansion

Fineline Cube Jan 17, 2023

China-based X-ray imaging core component supplier Suzhou Powersite Electric Co., Ltd has reportedly raised hundreds...

Company Deals

Beijing Interbio Secures Pre-Series A Funding for SPR Technology Expansion

Fineline Cube Jan 17, 2023

Beijing Interbio Biology & Technology Co., Ltd, a China-based company specializing in surface plasmon resonance...

Company Drug

CStone’s RET Inhibitor Gavreto Approved in Taiwan for Lung and Thyroid Cancers

Fineline Cube Jan 17, 2023

CStone Pharmaceuticals (HKG: 2616) has announced receiving marketing approval in Taiwan for its RET inhibitor...

Company Deals

Ascletis Partners with Simcere for Ritonavir Supply in COVID-19 Drug Development

Fineline Cube Jan 17, 2023

China-based Ascletis Pharma Inc. (HKG: 1672) has announced that its wholly-owned subsidiary Ascletis Pharmaceuticals Co.,...

Company Drug

Simcere’s COVID-19 Drug SIM0417 Accepted for Special Review by NMPA

Fineline Cube Jan 17, 2023

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced that the National Medical Products Administration (NMPA)...

Company Drug

Bristol-Myers Squibb’s Opdivo Secures Two New Approvals for Esophageal Cancer in China

Fineline Cube Jan 17, 2023

US-based pharmaceutical giant Bristol-Myers Squibb (BMS, NYSE: BMY) has received two new indication approvals in...

Company Drug

Henlius’ PD-1 Inhibitor HanSiZhuang Approved for First-Line SCLC Indication

Fineline Cube Jan 17, 2023

Shanghai Henlius Pharmaceutical Co., Ltd (HKG: 2696) has announced receiving another indication approval from China’s...

Company Medical Device

Agilis Robotics Completes Successful Animal Testing for Surgical Robot

Fineline Cube Jan 17, 2023

Hong Kong-based Agilis Robotics Ltd has successfully completed a second round of live animal testing...

Company Deals

CARsgen and Huadong Medicine Partner to Commercialize BCMA CAR-T Product CT053 in China

Fineline Cube Jan 17, 2023

China-based CARsgen Therapeutics Holdings Limited (HKG: 2171), a leading developer of innovative CAR T-cell therapies,...

Company Deals

Tongshu Gene Partners with LC Gene to Distribute Gene Mutation Detection Kit in China

Fineline Cube Jan 17, 2023

China-based gene testing service providers Tongshu Gene and LC Gene Diagnostics (Hangzhou) Co., Ltd. have...

Company Drug

3D Medicines’ 3D185 Receives Orphan Drug Designation for Gastric Cancer

Fineline Cube Jan 16, 2023

China-based oncology specialist 3D Medicines (HKG: 1244) has announced receiving orphan drug designation (ODD) status...

Posts pagination

1 … 576 577 578 … 670

Recent updates

  • Zai Lab Announces Executive Leadership Reshuffle as COO Josh Smiley Steps Down After Nearly Four Years
  • Allergan Aesthetics Secures CHMP Positive Opinion for Boey (TrenibotulinumtoxinE) in Glabellar Lines Treatment Across European Economic Area
  • Lupeng Pharma Enrolls First Patient in Global Phase 3 ROCKET-CLL Trial of Fourth-Gen BTK Inhibitor Rocbrutinib vs. Pirtobrutinib
  • Eli Lilly’s Retatrutide Delivers Breakthrough Weight Loss Results in Phase 3 TRIUMPH-1 Trial for Obesity Treatment
  • Merck KGaA Launches Phase III PROCEADE-CRC-03 Trial for First-in-Class CEACAM5 ADC Precemtabart Tocentecan in Metastatic Colorectal Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Zai Lab Announces Executive Leadership Reshuffle as COO Josh Smiley Steps Down After Nearly Four Years

Company Drug

Allergan Aesthetics Secures CHMP Positive Opinion for Boey (TrenibotulinumtoxinE) in Glabellar Lines Treatment Across European Economic Area

Company Drug

Lupeng Pharma Enrolls First Patient in Global Phase 3 ROCKET-CLL Trial of Fourth-Gen BTK Inhibitor Rocbrutinib vs. Pirtobrutinib

Company Drug

Eli Lilly’s Retatrutide Delivers Breakthrough Weight Loss Results in Phase 3 TRIUMPH-1 Trial for Obesity Treatment

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.